Maze Therapeutics Profit Margin

The latest profit margin for MAZE is -667.95% as of June 2026. That compares with -4831.84% in the prior-year period — up 86.2% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Maze Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MAZE's profit margin moved from -4831.84% to -667.95% — a 86.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Maze Therapeutics's valuation or profitability profile.

Against Healthcare companies, MAZE currently prints -667.95% for profit margin, while the sector average sits near 10.58%. That is roughly 6413.0% below the sector mean. Large gaps often invite a closer look at Maze Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Maze Therapeutics converts resources into returns. At -667.95%, MAZE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4831.84% in the prior-year period — up 86.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MAZE's profit margin (-667.95%), review year-over-year change from -4831.84%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.